Attovia Therapeutics
Jing Zhang is currently the Associate Director of Biology at Attovia Therapeutics. Prior to this role, Jing worked as a Principal Scientist and Senior Scientist at Zai Lab, focusing on oncology R&D pipelines and target validation activities. Jing also has experience as a Senior Scientist at Immutics, specializing in immune-oncology projects. Jing's research background includes investigating immune regulation mechanisms in mouse models of various diseases at Michigan State University. Jing holds a Doctor of Philosophy in Microbiology and Immunology from the National University of Singapore and a Bachelor's degree in Biological/Biosystems Engineering from Tianjin University.
Attovia Therapeutics
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.